- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Ikena Oncology, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 09.06. | Ikena Oncology, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 30.05. | Ikena Oncology, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 20.05. | Ikena Oncology, Inc. - S-4/A, Registration of securities, business combinations | 2 | SEC Filings | ||
| 08.05. | Ikena Oncology, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 07.05. | Ikena Oncology, Inc. - S-4/A, Registration of securities, business combinations | 4 | SEC Filings | ||
| 21.04. | Ikena Oncology, Inc. - S-4/A, Registration of securities, business combinations | 2 | SEC Filings | ||
| 18.03. | Ikena Oncology, Inc. - S-4, Registration of securities, business combinations | 4 | SEC Filings | ||
| IKENA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 06.03. | Ikena Oncology, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 23.12.24 | Ikena Oncology, Inc.: Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement | 193 | GlobeNewswire (Europe) | Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function The transaction... ► Artikel lesen | |
| 07.11.24 | Ikena Oncology, Inc.: Ikena Oncology Reports Third Quarter 2024 Financial Results | 224 | GlobeNewswire (Europe) | BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena," "Company") today announced financial results for the third quarter ended September 30, 2024, and provided an... ► Artikel lesen | |
| 08.08.24 | Ikena Oncology, Inc.: Ikena Oncology Reports Second Quarter 2024 Financial Results | 194 | GlobeNewswire (Europe) | BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena," "Company") today announced financial results for the second quarter ended June 30, 2024, and provided an update... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,170 | +0,42 % | Aurubis, BASF, Evotec, Redcare Pharmacy, ThyssenKrupp, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BIOGEN | 112,20 | -0,75 % | Große Kursgewinne für den Anteilsschein von Biogen (110,8649 €) | Zu den großen Gewinnern an der Börse zählt am Dienstag die Aktie von Biogen . Das Wertpapier steigt deutlich. Zu den Performancebesten des Tages gehört heute die Biogen-Aktie mit einem Wertanstieg von... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,115 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
| MAINZ BIOMED | 1,430 | 0,00 % | Mainz Biomed Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| VIKING THERAPEUTICS | 23,995 | +0,23 % | Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity | ||
| TREVENA | 0,153 | 0,00 % | Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc. ... | NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 4,630 | -2,11 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option | ||
| GALAPAGOS NV | 24,580 | -0,49 % | Galapagos NV: Galapagos Appoints Aaron Cox as Chief Financial Officer | Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership
Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated... ► Artikel lesen | |
| CENTOGENE | 0,092 | 0,00 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 3,120 | -1,42 % | Cardiff Oncology, Inc.: Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC | - Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development... ► Artikel lesen | |
| COHERUS ONCOLOGY | 0,699 | +1,72 % | Coherus Oncology, Inc. - 8-K, Current Report | ||
| SENSEI BIOTHERAPEUTICS | 2,813 | -100,00 % | XFRA FA20,0RA0,4070: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILFORWARD AIR CORP.... ► Artikel lesen | |
| AC IMMUNE | 1,710 | -2,17 % | AC Immune SA: AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update | AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseasesPositive... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,018 | -4,63 % | CytomX Q2 2025 Präsentationsfolien: CX-2051 zeigt vielversprechende Phase-1-Ergebnisse bei Darmkrebs | ||
| CYTOKINETICS | 29,000 | -2,03 % | Cytokinetics, Incorporated: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2025 it granted stock options to purchase an aggregate of... ► Artikel lesen |
IKENA ONCOLOGY INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,020 (+1,53 %) liegt der Kurs bei 1,330 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IKENA ONCOLOGY INC finden Sie auf Wallstreet Online.